MARKET

EXEL

EXEL

Exelixis Inc
NASDAQ
50.13
-0.97
-1.90%
After Hours: 50.44 +0.31 +0.62% 19:59 05/15 EDT
OPEN
51.09
PREV CLOSE
51.10
HIGH
51.31
LOW
49.59
VOLUME
2.07M
TURNOVER
--
52 WEEK HIGH
51.63
52 WEEK LOW
33.76
MARKET CAP
12.60B
P/E (TTM)
16.61
1D
5D
1M
3M
1Y
5Y
1D
Prediction: This Stock Could Double By 2031
The Motley Fool · 1d ago
Why Exelixis (EXEL) Is Up 5.3% After Revving Buybacks And Spotlighting Zanzalintinib Pipeline Potential
Simply Wall St · 3d ago
Weekly Report: what happened at EXEL last week (0504-0508)?
Weekly Report · 6d ago
A Look At Exelixis (EXEL) Valuation After Strong Q1 2026 Results And Zanzalintinib FDA Milestone
Simply Wall St · 05/09 16:47
Top Exelixis Insiders Quietly Unload Major Stakes in High-Value Stock Sales
TipRanks · 05/09 02:04
Exelixis director Mary C. Beckerle disposes 7,712 shares for $373,646.4
PUBT · 05/08 23:04
Exelixis Director Maria C. Freire disposes 20,634 shares for $949,164
PUBT · 05/08 23:04
Exelixis director George Poste disposes 60,000 shares for $2.74 million
PUBT · 05/08 23:04
More
About EXEL
Exelixis, Inc. is an oncology company. The Company has produced four marketed pharmaceutical products, two of which are formulations of its flagship molecule, cabozantinib. It is also advancing and evolving its product pipeline portfolio, including its lead investigational asset, zanzalintinib. Cabozantinib is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET and has been also approved as CABOMETYX tablets for advanced renal cell carcinoma, for previously treated hepatocellular carcinoma and for previously treated, radioactive iodine-refractory differentiated thyroid cancer, and as COMETRIQ capsules for progressive, metastatic medullary thyroid cancer. The Company's other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor approved the treatment of hypertension in Japan.

Webull offers Exelixis Inc stock information, including NASDAQ: EXEL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EXEL stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading EXEL stock methods without spending real money on the virtual paper trading platform.